Table 2.

Initial treatment provided for all muscle-invasive, non-advanced bladder cancer patients in the Netherlands diagnosed in 2018–2020, by clinical T-stage and sex

	Men		Women		Standardized differences
	N	%	N	%
All stages	2492	100	992	100
Treatment
RC + NAT	330	13	151	15	0.13
RC−NAT	804	32	286	29
Trimodal therapy	331	13	106	11
Radiotherapy	484	19	207	21
Systemic treatment	52	2	24	2
Other/none*	491	20	218	22
Curative treatment**
Yes (RC/TMT)	1465	59	543	55	0.08
No	1027	41	449	45
cT2, N0, M0	1803	100	637	100
Treatment
RC + NAT	182	10	75	12	0.12
RC−NAT	622	34	201	32
Trimodal therapy	254	14	83	13
Radiotherapy	367	20	140	22
Systemic treatment	20	1	8	1
Other/none*	358	20	130	20
Curative treatment**
Yes (RC/TMT)	1058	59	359	56	0.03
No	745	41	278	44
cT3, N0, M0	552	100	259	100
Treatment
RC + NAT	115	21	59	23	0.15
RC−NAT	156	28	68	26
Trimodal therapy	67	12	21	8
Radiotherapy	99	18	52	20
Systemic treatment	20	4	9	3
Other/none*	95	17	50	19
Curative treatment**
Yes (RC/TMT)	338	61	148	57	0.13
No	214	39	111	43
cT4a, N0, M0	137	100	96	100
Treatment
RC + NAT	33	24	17	18	0.37
RC−NAT	26	19	17	18
Trimodal therapy	10	7	2	2
Radiotherapy	18	13	15	16
Systemic treatment	12	9	7	7
Other/none*	38	28	38	40
Curative treatment**
Yes (RC/TMT)	69	50	36	38	0.25
No	68	50	60	63

RC  radical cystectomy; NAT  neoadjuvant treatment, including chemotherapy and immunotherapy; TMT  trimodal therapy

^*Other/none includes local treatments such as transurethral resection of the tumor, bladder instillations and partial cystectomies

**Curative treatment includes radical cystectomy with or without neoadjuvant treatment and trimodality treatment